Biomea Fusion AI Stock Analysis
Want to see BMEA full AI Analyst Report?
Biomea Fusion (BMEA) AI Stock Analysis
Biomea Fusion
(NASDAQ:BMEA)
The score is held down primarily by weak financial fundamentals (pre-revenue, persistent losses, ongoing cash burn, and sharply reduced equity) and bearish technicals (price below all key moving averages and negative MACD). A positive offset comes from improving loss/cash burn trajectory and a constructive Phase 1 update for BMF-650, but these are not enough to outweigh current funding and trend risks.
Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $38.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.21M
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 2.02
- Revenue Growth
- ―
- EPS Growth
- 87.11%
- Country
- US
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Biomea Fusion Business Overview & Revenue Model
Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALE...
Biomea Fusion Financial Statement Overview
Summary
Pre-revenue with ongoing losses and negative free cash flow, keeping financing risk elevated. Positives include a meaningful improvement in net loss and cash burn versus prior years and low leverage, but equity has fallen sharply over time, reducing balance-sheet cushion.
Income Statement
12Very NegativeBalance Sheet
46NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -93.00K | -1.41M | 0 | 0 | 0 | 0 |
| EBITDA | -22.19M | -60.39M | -136.68M | -115.74M | -81.14M | -41.32M |
| Net Income | -22.31M | -61.80M | -138.43M | -117.25M | -81.83M | -41.57M |
Balance Sheet | ||||||
| Total Assets | 28.10M | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M |
| Cash, Cash Equivalents and Short-Term Investments | 26.40M | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M |
| Total Debt | 506.00K | 1.59M | 8.77M | 10.30M | 2.29M | 2.85M |
| Total Liabilities | 20.51M | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M |
| Stockholders Equity | 7.59M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M |
Cash Flow | ||||||
| Free Cash Flow | -43.32M | -70.37M | -120.26M | -99.96M | -63.45M | -38.61M |
| Operating Cash Flow | -43.32M | -70.37M | -119.89M | -96.59M | -62.42M | -35.44M |
| Investing Cash Flow | 550.00K | 0 | -362.00K | -2.22M | 27.34M | -33.35M |
| Financing Cash Flow | 22.53M | 67.90M | 1.67M | 163.80M | 1.24M | 153.19M |
Biomea Fusion Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 1.03, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 39.71 is Neutral, neither overbought nor oversold. The STOCH value of 47.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMEA.
Biomea Fusion Risk Analysis
Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskBiomea Fusion Peers Comparison
Overall Rating
AGEN57Neutral
INO55Neutral
OVID52Neutral
BMEA45Neutral
ATOS42Neutral
SEER40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | $277.81M | 8.35 | -15.48% | ― | 25.38% | ― | |
| 55Neutral | $320.29M | -2.15 | -9999.00% | ― | 63.93% | 68.94% | |
| 52Neutral | $441.63M | -13.29 | -23.38% | ― | -78.05% | 63.85% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $42.76M | -1.86 | -131.27% | ― | ― | 87.11% | |
| 42Neutral | $17.46M | -0.45 | -117.07% | ― | ― | -10.80% | |
| 40Underperform | $77.30M | -1.20 | -27.03% | ― | -14.56% | 16.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BMEA | Biomea Fusion Inc | 0.59 | -0.39 | -40.00% | |
| AGEN | Agenus Inc. | 6.14 | 1.92 | 45.50% | |
| INO | Inovio Pharmaceuticals | 1.71 | -0.05 | -2.84% | |
| ATOS | Atossa Therapeutics, Inc. | 1.75 | -9.95 | -85.05% | |
| OVID | Ovid Therapeutics | 2.34 | 0.94 | 67.14% | |
| SEER | Seer, Inc. | 1.39 | -0.58 | -29.70% |
Biomea Fusion Corporate Events
Biomea Fusion Reports Phase 1 Results for BMF-650
PositiveOn October 13, 2026, Biomea Fusion hosted a conference call and webcast to present topline results from its ongoing Phase 1 GLP-131 clinical trial of BMF-650 in otherwise healthy overweight or obese adults. The company simultaneously released a press...
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
NeutralOn September 22, 2026, Biomea Fusion, Inc. reported an updated timeline for topline results from its ongoing Phase I GLP-131 clinical trial of BMF-650, conducted in obese but otherwise healthy volunteers. The company now expects to release these init...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
